Docket No.: 14129-00001-US

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Carsten Hopf

Application No.: 10/570,909

Filed: March 3, 2006

Art Unit: 1633

For: TREATMENT OF NEURODEGENERATIVE

Examiner: Hill, Kevin Kai

Confirmation No.: 1220

DISEASES

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed October 23, 2006, Applicants hereby provisionally elect Group I, claims 7-11, and species (i), an agent that modulates gamma secretase, with traverse. Applicants believe that there is no undue burden on the Examiner to search this invention. For the above reason, Applicants respectfully request that this restriction requirement be withdrawn.

This response is filed within one-month period for response from the mailing of the Office Communication. No fee is believed due. However, if a fee is due, please charge our Deposit Account No. 03-2775, under Order No. 14129-00001-US from which the undersigned is authorized to draw.

Respectfully submitted,

Hui-Ju Wu

Registration No.: 57,209

CONNOLLY BOVE LODGE & HUTZ LLP

1007 North Orange Street

P.O. Box 2207

Wilmington, Delaware 19899

(302) 658-9141

(302) 658-5614 (Fax)

Agent for Applicants

496397_1.DOC